Welcome!

News Feed Item

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

NEW YORK, April 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

http://www.reportlinker.com/p02063647/Gastroesophageal-GE-Junction-Carcinomas-Global-Clinical-Trials-Review-H1-2014.html

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014" provides data on the Gastroesophageal (GE) Junction Carcinomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastroesophageal (GE) Junction Carcinomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastroesophageal (GE) Junction Carcinomas. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Introduction 7
Gastroesophageal (GE) Junction Carcinomas 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Gastroesophageal (GE) Junction Carcinomas 26
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Gastroesophageal (GE) Junction Carcinomas 35
May 16, 2012: Amgen Presents Results From Exploratory Biomarker Analysis Of Rilotumumab 35
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
Amgen Inc. 38
Clinical Trial Overview of Amgen Inc. 38
Novartis AG 39
Clinical Trial Overview of Novartis AG 39
Bristol-Myers Squibb Company 40
Clinical Trial Overview of Bristol-Myers Squibb Company 40
Eli Lilly and Company 41
Clinical Trial Overview of Eli Lilly and Company 41
C. H. Boehringer Sohn AG & Co. KG 42
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 42
Dainippon Sumitomo Pharma Co., Ltd. 43
Clinical Trial Overview of Dainippon Sumitomo Pharma Co., Ltd. 43
Aphton Corporation (Inactive) 44
Clinical Trial Overview of Aphton Corporation (Inactive) 44
Amgen research GmbH 45
Clinical Trial Overview of Amgen research GmbH 45
Clinical Trial Overview of Top Institutes / Government 46
National Cancer Institute 46
Clinical Trial Overview of National Cancer Institute 46
North Central Cancer Treatment Group 48
Clinical Trial Overview of North Central Cancer Treatment Group 48
Case Comprehensive Cancer Center 49
Clinical Trial Overview of Case Comprehensive Cancer Center 49
Stanford University 50
Clinical Trial Overview of Stanford University 50
Sidney Kimmel Comprehensive Cancer Center 51
Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center 51
Memorial Sloan Kettering Cancer Center 52
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 52
Southwest Oncology Group 53
Clinical Trial Overview of Southwest Oncology Group 53
University of Pittsburgh 54
Clinical Trial Overview of University of Pittsburgh 54
Fox Chase Cancer Center 55
Clinical Trial Overview of Fox Chase Cancer Center 55
The University of Texas M. D. Anderson Cancer Center 56
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 56
Five Key Clinical Profiles 57
Appendix 104
Abbreviations 104
Definitions 104
Research Methodology 105
Secondary Research 105
About GlobalData 106
Contact Us 106
Disclaimer 106
Source 107

List of Tables

Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Region, 2014* 8
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 15
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Phase, 2014* 22
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 23
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Suspended Clinical Trials, 2014* 26
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Gastroesophageal (GE) Junction Carcinomas Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 30
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 37
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 38
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 39
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 40
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 41
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 42
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Dainippon Sumitomo Pharma Co., Ltd., 2014* 43
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Aphton Corporation (Inactive), 2014* 44
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen research GmbH, 2014* 45
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 46
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 48
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 49
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 50
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2014* 51
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 52
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 53
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 54
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Fox Chase Cancer Center, 2014* 55
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 56

List of Figures
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 15
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Phase (%), 2014* 22
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 23
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Gastroesophageal (GE) Junction Carcinomas Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 30
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
GlobalData Methodology 105

To order this report: Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02063647/Gastroesophageal-GE-Junction-Carcinomas-Global-Clinical-Trials-Review-H1-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today the Docker Meets Kubernetes – Intro into the Kubernetes World, being held June 9, 2016, in conjunction with 18th Cloud Expo | @ThingsExpo, at the Javits Center in New York, NY. Register for 'Docker Meets Kubernetes Workshop' Here! This workshop led by Sebastian Scheele, co-founder of Loodse, introduces participants to Kubernetes (container orchestration). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, participants learn ...
The IoT is changing the way enterprises conduct business. In his session at @ThingsExpo, Eric Hoffman, Vice President at EastBanc Technologies, discuss how businesses can gain an edge over competitors by empowering consumers to take control through IoT. We'll cite examples such as a Washington, D.C.-based sports club that leveraged IoT and the cloud to develop a comprehensive booking system. He'll also highlight how IoT can revitalize and restore outdated business models, making them profitable...
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
Customer experience has become a competitive differentiator for companies, and it’s imperative that brands seamlessly connect the customer journey across all platforms. With the continued explosion of IoT, join us for a look at how to build a winning digital foundation in the connected era – today and in the future. In his session at @ThingsExpo, Chris Nguyen, Group Product Marketing Manager at Adobe, will discuss how to successfully leverage mobile, rapidly deploy content, capture real-time d...
In his session at 18th Cloud Expo, Andrew Cole, Director of Solutions Engineering at Peak 10, will discuss how the newest technology advances are reducing the cost and complexity of traditional business continuity and disaster recovery solutions. Attendees will: Learn why having a full disaster recovery strategy is more important now than ever before Explore the key drivers of a successful disaster recovery solution Achieve measurable operational and business value from a disaster recovery ...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. Commvault can ensure protection, access and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his general session at 18th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Part...
SYS-CON Events announced today that Hanu Software will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Leveraging best-in-class people, processes, and technologies, Hanu provides high-quality, high-value software development and business process outsourcing services to independent software vendors (ISVs) and enterprises.
What a difference a year makes. Organizations aren’t just talking about IoT possibilities, it is now baked into their core business strategy. With IoT, billions of devices generating data from different companies on different networks around the globe need to interact. From efficiency to better customer insights to completely new business models, IoT will turn traditional business models upside down. In the new customer-centric age, the key to success is delivering critical services and apps wit...
SYS-CON Events announced today that ContentMX, the marketing technology and services company with a singular mission to increase engagement and drive more conversations for enterprise, channel and SMB technology marketers, has been named “Sponsor & Exhibitor Lounge Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York City, New York. “CloudExpo is a great opportunity to start a conversation with new prospects, but what happens after the...
Join us at Cloud Expo | @ThingsExpo 2016 – June 7-9 at the Javits Center in New York City and November 1-3 at the Santa Clara Convention Center in Santa Clara, CA – and deliver your unique message in a way that is striking and unforgettable by taking advantage of SYS-CON's unmatched high-impact, result-driven event / media packages.
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, will provide an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life ...
SYS-CON Events announced today that BMC Software has been named "Siver Sponsor" of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2015 at the Javits Center in New York, New York. BMC is a global leader in innovative software solutions that help businesses transform into digital enterprises for the ultimate competitive advantage. BMC Digital Enterprise Management is a set of innovative IT solutions designed to make digital business fast, seamless, and optimized from mainframe to mo...
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in Embedded and IoT solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and ...
SYS-CON Events announced today that MobiDev will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex software systems for startups and enterprises. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobile software company with over 200 develope...